Type 2 diabetes in adults with sickle cell disease: can we dive deeper?

Skinner, Sarah; Nader, Élie; Connes, Philippe

doi:10.1111/bjh.15951

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DM is also common in the US and is classified as a family of metabolic disorders (including CFRD, type 1 DM, and T2D) caused by defects in insulin secretion, insulin function, or both, resulting in hyperglycemia and small‐vessel vasculopathic changes 4 . Glucose intolerance from CFRD has similar clinical features as other forms of DM, 11 and while DM in general is common among the African‐American population, 12 the true prevalence of DM in patients with SCD remains unknown 1,2 …”

Section: Discussionmentioning

confidence: 99%

“…The true prevalence of diabetes mellitus (DM) among patients with sickle cell disease (SCD) in the United States (US) is unknown, in part from limitations of glycated hemoglobin A (HbA 1c ) assays since hemolysis and the presence of sickle hemoglobin (HbS) impacts the reliability of HbA 1c measurements 1,2 . HbA 1c measurements can also be impacted by blood transfusions, a commonly used therapy in SCD due to the mitigating properties of red blood cells (RBCs) with hemoglobin A (HbA) in the circulation of SCD patients 3 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hemoglobin A_1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy

McLean

Wright

deJong

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

In patients with sickle cell disease (SCD) and diabetes mellitus (DM), hemoglobin A1c (HbA1c) is unreliable and the American Diabetes Association recommends monitoring long‐term glycemia by measuring serum glucose, but use of serum fructosamine (SF), a measurement independent of red cell lifespan, has been reported. SF as a screen for DM in SCD, however, is not standardized and its relationship to serum glucose has not been validated. Further, screening for DM was not adequately addressed in the 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines for SCD management. Blood transfusions, an important treatment for some patients with SCD, can also impact HbA1c. We present a case of a patient with SCD and cystic fibrosis‐related diabetes on monthly chronic transfusions therapy (CTT) who had well‐correlated “steady state” HbA1c and SF levels over time, suggesting for the first time these markers may actually be useful when following long‐term glycemic control in patients with SCD on CTT programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Hemoglobin A_1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy

McLean

Wright

deJong

et al. 2020

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

show abstract